ArticleAddiction biology2020

A randomized, double-blind, placebo-controlled study of the kappa opioid receptor antagonist, CERC-501, in a human laboratory model of smoking behavior.

Jermaine D Jones et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.